Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FDA blasts Isner's VEGF trials

The FDA has accused Vascular Genetics Inc. founder Jeffrey Isner of violating regulations governing the conduct of clinical trials and human subject protections, putting subjects at risk in trials of Vascular Endothelial Growth Factor Plasmid (VEGF-2) and jeopardizing the accuracy of the trial results.

The trials involved the use of VEGF-2 to treat coronary artery disease and peripheral artery disease. In

Read the full 613 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers